Intramural Funding Opportunities
Deadline: July 15
Give Breast Cancer the Boot RFA
Give Breast Cancer the Boot (GBCTB) funds are being made available through this RFA to members of the UCSF community to support breast cancer research or patient support services.
Deadline: July 6
Target Validation Initiative RFA
The aim of this initiative, which is in partnership with ShangPharma Innovation South San Francisco, leveraging the support of their affiliated CRO ChemPartner, is to identify and support the translation of UCSF’s world-class research into novel treatments for specific cancers.
Deadline: July 25
Astellas Oncology C3 Prize Innovation Challenge
Deadline: Sept 6
Pfizer and RCNi – Providing Access to Learning Resources for Nurses in Africa
Preliminary submission deadline: July 2
SU2C-CRUK Pediatric Brain Cancer Dream Team
We're calling for applications from incredible scientific minds from across disciplines, institutions and countries to tackle critical translational research questions in pediatric brain cancer. The SU2C-CRUK Pediatric Brain Cancer Dream Team research grant provides up to $10m over four years.
Deadline: August 6
Beckman Young Investigator Program
provides research support to the most promising young faculty members in the early stages of their academic careers in the chemical and life sciences, particularly to foster the invention of methods, instruments and materials that will open up new avenues of research in science.
Preliminary submission deadline: September 6
CRUK Brain Tumour Awards
Supports multidisciplinary approaches to tackle key basic and translational questions in brain tumour research. We’re providing up to up to £10m per award over five years to support the boldest and most innovative projects to drive impact for patients.
- Due June 16: Research on the Health of Transgender and Gender Nonconforming Populations (R21 Clinical Trial Optional) (PA-18-728)
- Due June 19: Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed) (PAR-18-731)
- LOI due July 17: Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R21 Clinical Trial Not Allowed)
- LOI due July 17: Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional)
To view all NCI funding opportunities, search here